• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Is Efficacy of Tezepelumab Independent of Severe Asthma Phenotype?

作者信息

Brusselle Guy, Riemann Sebastian

机构信息

Erasmus Medical Center, Respiratory Medicine and Epidemiology, Rotterdam, Netherlands.

Ghent University Hospital, Respiratory Medicine, Ghent, Belgium;

出版信息

Am J Respir Crit Care Med. 2023 Apr 19;208(1):1-3. doi: 10.1164/rccm.202304-0700ED.

DOI:10.1164/rccm.202304-0700ED
PMID:37074294
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10870843/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd2d/10870843/c77d6559491a/rccm.202304-0700EDf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd2d/10870843/c77d6559491a/rccm.202304-0700EDf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd2d/10870843/c77d6559491a/rccm.202304-0700EDf1.jpg

相似文献

1
Is Efficacy of Tezepelumab Independent of Severe Asthma Phenotype?tezepelumab的疗效是否独立于重度哮喘表型？
Am J Respir Crit Care Med. 2023 Apr 19;208(1):1-3. doi: 10.1164/rccm.202304-0700ED.
2
Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study.tezepelumab治疗有严重过敏性哮喘证据患者的疗效：3期NAVIGATOR研究结果
Clin Exp Allergy. 2023 Apr;53(4):417-428. doi: 10.1111/cea.14256. Epub 2022 Dec 12.
3
Tezepelumab in the Treatment of Uncontrolled Severe Asthma.特泽布尔单抗治疗未控制的重度哮喘。
Ann Pharmacother. 2023 Jan;57(1):62-70. doi: 10.1177/10600280221095540. Epub 2022 May 10.
4
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.特泽布尔单抗治疗严重、未控制哮喘患者的长期安全性和有效性（DESTINATION）：一项随机、安慰剂对照扩展研究。
Lancet Respir Med. 2023 May;11(5):425-438. doi: 10.1016/S2213-2600(22)00492-1. Epub 2023 Jan 23.
5
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy.特泽佩umab治疗重度、未控制哮喘和常年性过敏患者的疗效
J Allergy Clin Immunol Pract. 2021 Dec;9(12):4334-4342.e6. doi: 10.1016/j.jaip.2021.07.045. Epub 2021 Aug 3.
6
Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma.抗TSLP抗体Tezepelumab治疗哮喘的临床研究现状总结。
Allergol Int. 2023 Jan;72(1):24-30. doi: 10.1016/j.alit.2022.11.006. Epub 2022 Dec 2.
7
The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials.特泽佩umab对难治性重度哮喘的影响：随机对照试验的系统评价
Cureus. 2022 Dec 3;14(12):e32156. doi: 10.7759/cureus.32156. eCollection 2022 Dec.
8
Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR.在NAVIGATOR研究中tezepelumab对伴有鼻息肉的重度、未控制哮喘患者的疗效
J Asthma Allergy. 2023 Sep 4;16:915-932. doi: 10.2147/JAA.S413064. eCollection 2023.
9
Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.特泽布尔单抗与其他生物制剂治疗重度哮喘的比较：系统评价和间接治疗比较。
J Med Econ. 2022 Jan-Dec;25(1):679-690. doi: 10.1080/13696998.2022.2074195.
10
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Analysis of the Phase 2b PATHWAY Study.特泽佩umab在有和无鼻息肉的重度、未控制哮喘患者中的疗效：2b期PATHWAY研究分析
J Asthma Allergy. 2021 Feb 3;14:91-99. doi: 10.2147/JAA.S288260. eCollection 2021.

引用本文的文献

1
Biologic Therapies for Severe Asthma: Current Insights and Future Directions.重症哮喘的生物疗法：当前见解与未来方向
J Clin Med. 2025 May 2;14(9):3153. doi: 10.3390/jcm14093153.
2
Positioning tezepelumab for patients with severe asthma: from evidence to unmet needs.定位特泽鲁单抗用于重度哮喘患者：从证据到未满足的需求。
J Int Med Res. 2024 Nov;52(11):3000605241297532. doi: 10.1177/03000605241297532.
3
Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab.儿童和青少年重症哮喘管理的新进展：聚焦度普利尤单抗和特泽鲁单抗。

本文引用的文献

1
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.特泽布尔单抗治疗重度、未控制哮喘的疗效：PATHWAY 和 NAVIGATOR 临床试验的汇总分析。
Am J Respir Crit Care Med. 2023 Jul 1;208(1):13-24. doi: 10.1164/rccm.202210-2005OC.
2
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.特泽布尔单抗治疗严重、未控制哮喘患者的长期安全性和有效性（DESTINATION）：一项随机、安慰剂对照扩展研究。
Lancet Respir Med. 2023 May;11(5):425-438. doi: 10.1016/S2213-2600(22)00492-1. Epub 2023 Jan 23.
3
Paediatr Drugs. 2023 Nov;25(6):677-693. doi: 10.1007/s40272-023-00589-4. Epub 2023 Sep 2.
4
Reply to Lipworth and Chan.对利普沃思和陈的回复。
Am J Respir Crit Care Med. 2023 Jul 15;208(2):212-213. doi: 10.1164/rccm.202305-0843LE.
5
Reply to Lipworth and Chan.对利普沃思和陈的回复。
Am J Respir Crit Care Med. 2023 Jul 15;208(2):211-212. doi: 10.1164/rccm.202305-0792LE.
6
Disconnect for Tezepelumab on Exacerbations, Symptoms, and Quality of Life in Type 2 Low Asthma.特泽佩umab对2型轻度哮喘急性加重、症状及生活质量的影响
Am J Respir Crit Care Med. 2023 Jul 15;208(2):211. doi: 10.1164/rccm.202304-0746LE.
Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma.
度普利尤单抗治疗未控制或依赖口服皮质类固醇的过敏性和非过敏性哮喘患者的疗效。
J Allergy Clin Immunol Pract. 2023 Mar;11(3):873-884.e11. doi: 10.1016/j.jaip.2022.11.044. Epub 2022 Dec 23.
4
Disease-modifying anti-asthmatic drugs.疾病修饰抗哮喘药物。
Lancet. 2022 Apr 23;399(10335):1664-1668. doi: 10.1016/S0140-6736(22)00331-2.
5
Biologic Therapies for Severe Asthma.重度哮喘的生物疗法
N Engl J Med. 2022 Jan 13;386(2):157-171. doi: 10.1056/NEJMra2032506.
6
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.特泽普单抗对中重度未控制哮喘（CASCADE）患者气道炎症细胞、重塑和高反应性的影响：一项双盲、随机、安慰剂对照、2 期临床试验。
Lancet Respir Med. 2021 Nov;9(11):1299-1312. doi: 10.1016/S2213-2600(21)00226-5. Epub 2021 Jul 10.
7
The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM).tezepelumab对哮喘患者气道对甘露醇高反应性的影响（UPSTREAM研究）
Eur Respir J. 2021 Dec 31;59(1). doi: 10.1183/13993003.01296-2021. Print 2022 Jan.
8
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.特泽布尔单抗在成人和青少年重症、未控制哮喘中的应用。
N Engl J Med. 2021 May 13;384(19):1800-1809. doi: 10.1056/NEJMoa2034975.
9
Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma.胸腺基质淋巴细胞生成素：在哮喘中的作用及其作为治疗靶点的潜力。
Expert Opin Ther Targets. 2020 Aug;24(8):777-792. doi: 10.1080/14728222.2020.1783242. Epub 2020 Jun 27.
10
Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘的效果与奥马珠单抗适应证的相关性。
Respir Med. 2019 Jul-Aug;154:69-75. doi: 10.1016/j.rmed.2019.06.004. Epub 2019 Jun 8.